NEW YORK, Sept. 05, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depositary Shares of Teva Pharmaceutical Industries Ltd. ("Teva") (NYSE:TEVA) between November 15, 2016 and August 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania. To get more information go to:
http://www.zlk.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company’s financial results and business prospects.
If you suffered a loss in Teva you have until October 23, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple Turns 50: From Garage Startup to AI Crossroads
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



